【迪哲医药：股价异常波动 与阿斯利康交易存不确定性】迪哲医药公告称，公司股票2026年7月13 - 15日连续三个交易日收盘价格涨幅偏离值累计达30%，属异常波动。近日，公司与阿斯利康签署《许可协议》，授予其全球独家开发、商业化舒沃哲®的权利，将获6亿美元首付款，最高4亿美元临床开发及5亿美元销售里程碑款，还有特许权使用费。该交易尚需股东会审议，最终生效要满足条件并获相关批准，存在不确定性。公司提醒投资者注意风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.